DiaSorin S.p.A. (DSRLF)
OTCMKTS
· Delayed Price · Currency is USD
104.69
0.00 (0.00%)
May 12, 2025, 4:00 PM EDT
DiaSorin Revenue
DiaSorin had revenue of 313.00M EUR in the quarter ending March 31, 2025, with 8.30% growth. This brings the company's revenue in the last twelve months to 1.21B, up 5.42% year-over-year. In the year 2024, DiaSorin had annual revenue of 1.19B with 3.24% growth.
Revenue (ttm)
1.21B EUR
Revenue Growth
+5.42%
P/S Ratio
4.45
Revenue / Employee
365.61K EUR
Employees
3,308
Market Cap
5.82B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.19B | 37.22M | 3.24% |
| Dec 31, 2023 | 1.15B | -212.93M | -15.64% |
| Dec 31, 2022 | 1.36B | 123.48M | 9.98% |
| Dec 31, 2021 | 1.24B | 356.35M | 40.43% |
| Dec 31, 2020 | 881.31M | 174.99M | 24.77% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Endo Inc. | 1.73B |
| Veradigm | 588.02M |
| Tian'an Technology Group | 1.78M |
| Glass House Brands | 200.90M |
| Elite Pharmaceuticals | 70.00M |
| Northwest Biotherapeutics | 1.38M |
| BioStem Technologies | 301.83M |
| American Oncology Network | 1.76B |
DiaSorin News
- 11 days ago - DiaSorin: Anticipate A Double-Digit EBITDA Growth Rate - Seeking Alpha
- 2 months ago - DiaSorin S.p.A. (DSRLF) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Italy's DiaSorin ex-Covid revenue in line with guidance - Reuters
- 6 months ago - Diagnostics group DiaSorin's nine-month adjusted core profit up 6% - Reuters
- 10 months ago - DiaSorin S.p.A. (DSRLF) Q2 2024 Earnings Call Transcript - Seeking Alpha
- 1 year ago - DiaSorin S.p.A. (DSRLF) Q4 2023 Earnings Call Transcript - Seeking Alpha
- 1 year ago - Diasorin 2023 revenue drops 14%, in line with guidance; shares fall - Reuters
- 1 year ago - DiaSorin S.p.A. (DSRLF) Q3 2023 Earnings Call Transcript - Seeking Alpha